Next Gen Antibodies and Cellular Therapy |
Opening remarks from the Chairman
Sophia Karagiannis, Ann White, ,
|
13:55 - 14:00 |
Keynote: PD-1 Antibodies are Transforming Cancer Care both as Mono- and Combination Therapy
|
14:00 - 14:30 |
Avidimabs, Fc engineering to enhanced the avidity of mabs
Lindy Durrant, Professor, Cancer Immunotherapy, University of Nottingham, UK
|
14:30 - 15:00 |
CAR T cell research solutions by Miltenyi Biotec
Marcello Stein , Global Product Manager, T Cell Immunology , Miltenyi Biotec, Germany
|
15:00 - 15:30 |
CAR T-cell immunotherapy of solid tumours: parallel learning from the clinic and lab
John Maher, Scientific Founder and Chief Scientific Officer, Leucid Bio
|
17:15 - 17:45 |
Monoclonal Antibodies and Cellular Therapy |
Accelerating ImmunoOncology research with Human Primary Cells
Manish Kumar, Product Manager Cells and Media, PromoCell
|
15:30 - 16:00 |
IgE class antibodies for cancer treatment: activating the tumour microenvironment
Sophia Karagiannis, Professor, Translational Cancer Immunology and Immunotherapy, Kings College London, UK
|
16:00 - 16:30 |
Networking and One-on-One Meetings on the event portal
|
16:30 - 16:45 |
In vitro T cell dysfunction / exhaustion-like assays for functional characterization and/or screening of immunomodulatory candidate drugs
Eden Kleiman , Senior Scientist Immuno-oncology, CrownBio
|
16:45 - 17:15 |
Development of the next generation immuno-modulators towards the clinic: A humanized anti-BTN3A antibody activating Vγ9Vδ2 T cells
Aude De Gassart , Director of Preclinical Research , ImCheck Therapeutics, France
|
17:45 - 18:15 |
A versatile Plug-and-Play platform, BiXAb, for development of bispecific antibodies with diverse set of mechanisms of action
Mustapha Faroudi , Director of Immuno Oncology, , Biomunex Pharmaceuticals
|
18:15 - 18:45 |
Selective T Cell Redirection (STR): The Art Triggering A Natural Yet Comprehensive Immune Response In Cold Tumors
Asher Nathan , CEO , NeoTX Therapeutics, Israel
|
18:45 - 19:15 |
Closing Remarks from Chairman
|
19:15 - 19:20 |
End of Day 1 and One-one-One Networking
|
19:20 - 19:20 |
Immune Checkpoint Inhibitors & Combination Strategies |
Opening remarks from the Chairman
Ali Roghanian, Assistant Professor, Cancer Immunology, University of Southampton, UK
|
13:55 - 14:00 |
Keynote: ICI and chemotherapy, why and how?
Stefan Glueck, Senior Vice President, Global Medical Affairs, Celgene
|
14:00 - 14:30 |
Enhanced Biomarker Discovery and Validation Using TMT® Proteomics
Illip Burmester, Ph.D. , Scientific Sales Support Europe, Proteome Sciences
|
14:30 - 15:00 |
Using CRISPR screens in immune cells to better understand the tumour-immune interface
Nicola McCarthy , Global Scientific Liaison , Horizon Discovery, UK
|
15:00 - 15:30 |
Pre-clinical & Translational Immuno-Oncology Developments |
Humanized Mouse Models for Immuno-Oncology Research
Bradlee Heckmann, CSO, Asha Therapeutics
|
15:30 - 16:00 |
Engineering humanized mouse models of haematological and solid malignancies
Ali Roghanian, Assistant Professor, Cancer Immunology, University of Southampton, UK
|
16:00 - 16:30 |
Networking and One-on-One Meetings on the event portal
|
16:30 - 16:45 |
Live Biotherapeutic MRx0518 induces broad anti-tumour immunity and demonstrates potential synergy with checkpoint inhibition
Marsilio Adriani, Principal Scientist, 4D Pharma
|
16:45 - 17:15 |
Enabling the expansive interrogation of a tumor and its microenvironment from a single sample for precision oncology biomarker discovery applications
Maik Pruess PhD, Senior Field Application Scientist , Personalis Inc
|
17:15 - 17:45 |
Accelerate Therapeutic Antibody and Viral Vectors Manufacturing Partnering with GenScript ProBio
Ben Xu, BD Director, Biologics Development, GenScript, USA
|
17:45 - 18:15 |
Strategies to enhance the efficacy of tumor antigen-specific CAR-based immunotherapy with solid tumors
Soldano Ferrone, Professor, Harvard University, USA
|
18:15 - 18:45 |
Integrin αvβ8-expressing tumor cells serve as a platform for TGF-β activation
Sam Shrivastava, Chief Executive Officer, Founder, Venn Therapeutics
|
18:45 - 19:15 |
Closing Remarks from Chairman
|
19:15 - 19:20 |
End of Day 1 and One-one-One Networking
|
19:20 - 19:20 |
|